Introduction
Zilpaterol hydrochloride (Zilmax, Intervet, South Africa) is an orally active type 2 β-agonist approved for use in feedlot cattle in South Africa, Mexico, and the United States (1). In feedlot cattle, feeding zilpaterol has been shown to improve average daily gain (ADG), feed efficiency, carcass yield grade, hot carcass weight (HCW), and dressing percentage in steers (2, 3) and in Holstein steers (4) when administered (dosage estimated based on average dry matter intake (DMI) and average weight reported in those studies) from 0.13 to 0.15 mg/kg live weight per day in the last 20 to 42 days of the feeding period. Likewise, in finishing lambs, zilpaterol supplementation at rates of 0.15 to 0.30 mg/kg live weight per day in the last 30 days of the feeding period increased ADG, feed efficiency, HCW, and dressing percentage, and it increased HCW, dressing percentage, and longissimus muscle (LM) area in ewe lambs (5) . Compared to male lambs, the male kids of milk/meat goat breeds generally have a lower growth rate and lower dressing percentage (6) . The latter can be partially explained by the greater visceral mass of goats and the fact that an appreciable proportion of energy expenditure can be attributed to the maintenance of visceral organs, especially the liver and gastrointestinal tract (7) . Researchers such as Lopez-Carlos et al. found that ZH supplementation to finishing lambs decreased the visceral organ mass and body fat, which would partially explain the role of zilpaterol in the enhancement of carcass dressing percentage and energetic efficiency (5) . Therefore, ZH supplementation could be expected to achieve a greater response in goats. Since ZH is approved as a food additive for feedlot cattle but is currently not approved for use in small ruminants, there is no available information about the effect of ZH supplementation on growth performance and carcass characteristics in male goats. Thus, the objective of this study was to evaluate feedlot performance, carcass traits, visceral mass, and the chemical composition and plasma metabolites of the LM of castrated goats fed ZH at 0.20 mg/kg of live bodyweight during the last 30 days of the finishing period. . Two weeks later, 16 kids were selected based on similar body weight and size and were randomly assigned to individual pens. The 16 pens used in the study were 0.96 m 2 with overhead shade, concrete floor, automatic waterers, and 0.40-m metallic feed bunks. Selected kids were fed the basal diet for 60 days before the trial started. During the pretrial period (60 days) and throughout the experiment (33 days), kids were fed twice daily at 0800 and 1600 hours. Daily feed allotments to each pen were adjusted to allow minimal (<5%) feed refusals in the feed bunk. The amounts of feed offered and feed refused were weighed daily. Feed bunks were visually assessed between 0740 and 0750 hours each morning, refusals were collected and weighed, and feed intake was determined. Adjustments to either increase or decrease daily feed delivery were provided at the afternoon feeding. Feed and refusal samples were collected daily for DM analysis, which involved oven drying the samples at 105 °C until no further weight loss occurred (8 (8) ). Goats that received ZH were fed the β-agonist for 30 days with a 3-day withdrawal period before harvest. To maintain the planned daily dosage of ZH, all kids were individually weighed weekly using electronic scales (PX 9000, Pand Ltd., Tehran, Iran) before the morning feed (0730 hours). The daily dosage of ZH was adjusted weekly based on the body weight and feed intake observed in the previous week.
Materials and methods

Growth performance data
The performance data were calculated from weights registered before the morning feed on day 1 and day 33 of the feeding trial. Initial BW was reduced by 4% to adjust for gastrointestinal tract contents, and all kids were fasted for 16 h before recording the final BW. Average daily gains were computed by subtracting the initial live Samples were immediately centrifuged for 15 min at 3000 × g at a temperature of 5 °C, and plasma was stored at -20 °C until analysis of glucose, triglycerides, and cholesterol. Plasma metabolites were quantified by spectrophotometry (UV-2100, Shimadzu, Kyoto, Japan) using a Diagnostic Chemicals Ltd. kit (Pars Azmoon, Iran, for glucose, triglycerides, and cholesterol).
Slaughter process and carcass data collection
At the end of the experiment, all kids were harvested. Kids were transported to the Rac industrial abattoir in the city of Karaj located 10 km from the research facilities. The time from unloading to harvest was 6 h. At the time of harvest gastrointestinal organs were separated and weighed, and HCWs were recorded. After carcasses were chilled for 48 h, lambs were utilized for measurement of fat thickness, LM area, and kidney-pelvic (KP) fat, which was removed from the hind saddle and weighed and reported as a percentage of carcass weight (9) . The dressing percentage was calculated by expressing HCW as a percentage of final live BW (9) . The difference between HCW and cold carcass weight (CCW) was used to calculate the percentage of cooling loss (9) . Each carcass was split down the midline of the vertebral column into two sides. The right side was used for the chemical and quality analysis of the LM. After carcass analyzing, they were immediately vacuum sealed and carried to the laboratory under cool conditions.
Data on organ mass
All tissue masses are reported on a fresh tissue basis. Organ mass was expressed as grams of fresh tissue per kilogram of final empty BW. Final empty BW (EBW) represents final BW minus the total weight of the digesta. Full viscera mass was calculated by the summation of all viscera components (stomach complex + small intestine + large intestine + liver + lungs + heart), including the digesta. Stomach complex was calculated as the digestafree sum of weights of the rumen, reticulum, omasum, and abomasum. To express organ mass on an EBW basis, fresh organ mass (g) was divided by final EBW (kg). ) for a completely randomized design. Treatment was considered as the fixed effect and goat as the random effect. The effects of treatments on visceral organ mass data (expressed as g/kg EBW) were evaluated using a one-way classification model. Goats were used as experimental units. In all cases, least square means and standard error are reported, with significance at P < 0.05 and main trends at P < 0.10.
Chemical analyses of longissimus muscle
Results
Feeding performance
The ADG, DMI, and gain efficiency (gain for feed, G:F) during the 60-day pretrial period were similar (P ³ 0.32) among preassigned treatment groups, averaging 0.135 ± 0.03 kg/day, 1.29 ± 0.08 kg/day, and 0.11 ± 0.004, respectively. The effects of zilpaterol supplementation on growth performance are presented in Table 2 . In comparison with the controls, ZH increased total weight gain (48.1%, P < 0.01) and ADG (47.9%, P = 0.02.) and reduced DMI (10.9%, P < 0.01); therefore, supplementation of ZH increased (P < 0.01) G:F by 65.2%.
Concentration of plasma metabolites
The effects of treatments on the plasma concentration of glucose, triglycerides, and cholesterol measured 1 h before feeding are shown in Table 3 . On day 1, the plasma levels of glucose, triglycerides, and cholesterol did not differ (P > 0.18) between treatments, averaging 114.76 ± 6.0, 49.52 ± 2.66, and 79.02 ± 4.85 mg/dL, respectively. However, on day 30, the goats fed with ZH had lower (P < 0.05) serum concentrations of glucose (12.5%), triglycerides (9.2%), and cholesterol (11.8%) than the controls.
Carcass characteristics and LM chemical and qualitative characteristics
The effects of treatments on carcass characteristics and the chemical composition of the LM are presented in Table 4 . Dietary ZH had no effect (P = 0.45) on cooling loss and increased (P < 0.01) HCW by 9.9%. As a result of an increase (P < 0.01) of the LM area by 20.4% and a reduction (P < 0.01) of KP fat by 33.3%, dressing percentage was increased (P < 0.01) by 3.7% in goats fed ZH. The composition of gain was also modified by ZH. The LM of goats fed ZH showed an increase (13.3%, P < 0.01) in protein concentration and a decrease (20.3%, P < 0.05) in fat content.
Visceral organs mass
The effects of treatments on fresh organ mass are presented in Table 5 . Supplemental ZH did not affect (P ≥ 0.14) the full viscera or stomach complex mass. The relative value of EBW/final BW was not affected by ZH supplementation, averaging 84.3%, but the EBW increased (6.1%, P = 0.03) and the relative values (g/kg final EBW) of heart/lungs and kidney weights decreased (P ≤ 0.04) by 10.4% and 13.9%, respectively.
Discussion
Feeding performance
Mahabadi is a native goat breed from western Iran for which there is limited information about growth performance and carcass characteristics. Nevertheless, the rate of gain and the carcass traits observed here for the control group in the last 33 days are similar to those reported for intact male Mahabadi goats finished at a similar initial BW and a comparable diet (10) . The results from the current study are 1 Control = no zilpaterol supplementation, ZH = supplemental zilpaterol dosed at 0.20 mg/kg BW daily. 2 Goat kids were withdrawn 16 h before weighing and slaughtering. 3 Full viscera = full viscera mass = (stomach complex + small intestine + large intestine + liver + lungs + kidney + heart) including digesta. 4 Stomach complex = (rumen + reticulum + omasum + abomasum), without digesta. 5 KPH = kidney-pelvic-heart fat.
consistent with results reported in feedlot cattle (1,2) and in feedlot lambs (5, 11) where ZH supplementation enhanced ADG and gain efficiency. We observed that the magnitude of the responses to ZH supplementation in terms of ADG and gain efficiency (Table 2 ) in the present study were greater (45.9% and 63.3%) than the average (32.95% and 26.17%) previously reported for ZH-fed finishing male lambs (5, 12) . The effects of ZH supplementation on DMI were less consistent. Although in the majority of studies involving feedlot cattle (13) ZH supplementation did not affect DMI, some reports indicated effects on DMI when cattle were fed ZH. To the best of our knowledge (1,2), only one study reported that zilpaterol supplementation increased feed intake, and it was reported in lambs (11) . There is no information regarding the effect of ZH on DMI in goats; however, as in the present study, in some studies ZH supplementation has been reported to result in depression of DMI in feedlot cattle. Vasconcelos et al.
(2) reported a linear decrease in the DMI of steers as the length of ZH supplementation increased from 20 to 40 days. In contrast, Montgomery et al. (1) observed that ZH supplementation decreased DMI by 6% in heifers but not in steers when ZH was included in the diet for 40 days. In a subsequent study, Montgomery et al. (1) reported a decrease in DMI in steers when ZH was fed for 30 days. The reasons for decreased feed intake when β-agonists are fed has not been elucidated, but it may involve both direct (e.g., tissue-specific) and indirect (e.g., endocrine) changes associated with fat and muscle metabolism (14).
Concentration of plasma metabolites
According to plasma metabolite results (Table 3) , the decrease in plasma glucose in the current study may be due to the fact that the rate of energy metabolism increases directly in relation to muscle mass; however, in ruminants, the effects of agonists on plasma metabolites are inconsistent. Although data on the effects of IGF-I on energy metabolism in ruminants are lacking, studies in hypophysectomed rats have shown that IGF-I exerts insulin-like effects on glucose metabolism and stimulates glycogen synthesis in skeletal muscle (15) . In accordance with our findings, significantly higher levels of net glycogen synthesis from glucose were observed in LM strips from clenbuterol-fed animals than in muscle strips from control sheep (16) . In contrast, Beermann et al. (16) observed that feeding cimaterol to growing lambs increased growth hormone and T4 concentrations but decreased insulin and IGF-I concentrations after 6 weeks. However, in subsequent studies, cimaterol supplementation in lambs did not affect IGF-I concentration but decreased T4 and markedly decreased (50%) insulin concentrations after 3 weeks of treatment (17) . Claeys et al. (18) also reported no change in IGF-I following chronic administration of clenbuterol to sheep. In the same manner, no effect on blood glucose content was detected when terbutaline or metaproterenol, both β-adrenergic agonists, were offered to sheep (19) . In nonruminant species, zilpaterol increased plasma glucose levels within 72 h, but significantly decreased glucose levels after 14 days (20) . As in the present study, Galbraith et al. (21) recorded significant reductions in plasma-free fatty acids at day 9, but observed an increase in plasma glucose concentration at day 49 in lambs treated with cimaterol. Likewise, Kim et al. (22) observed significant increases in the plasma concentrations of fatty acids and triglycerides following supplementation with 10 ppm of cimaterol.
Carcass characteristics
The increased dressing percentage in goats fed ZH explained 72.8% of the differential increase in gain observed in the ZH treatment. Increased carcass weight and dressing percentage and decreased KP fat has been a consistent response to ZH supplementation in lambs (6) . However, in the current study, the magnitude of these responses was two-fold greater for HCW and 22% lower for dressing percentage, and KP fat was decreased by 4% when compared to other studies. The potential for increased LM area as a result of ZH supplementation in feedlot cattle is well documented (1). However, in lambs, the magnitude of the response has been variable, ranging up to 30% (12) . The factors that affect the magnitude of responses to zilpaterol supplementation in terms of growth performance and carcass characteristics in small ruminants require further study, but may include growth potential, age at time of feeding zilpaterol, nutritional background, initial weight at the start of the finishing program, number of previous days on feed in feedlot, and final weight at time of harvest (23).
LM chemical and qualitative characteristics
About data gained for LM chemical characteristics in Table 4 , most of the β-agonists used in livestock result in increased lipolysis, decreased lipogenesis, or increased protein deposition by binding to the β 1 -or β 2 -adrenergic receptors (23) . The mechanism of these in vivo effects of β-agonists is not completely understood. Protein accretion is strongly influenced by calpastatin, which is one of the factors causing skeletal muscle hypertrophy (24) . Some studies indicated that the activity of calpastatin, the endogenous inhibitor of μ-and m-calpain, increases substantially during supplementation with type 2 β-agonists (25) , whereas others have suggested that improvements in protein accretion are due to an increase in protein. Like the present study, Baker et al. (26) reported an increase in protein and moisture content with a reduction in fat content in the hindquarter muscle of lambs fed clenbuterol (a β-agonist type 2). Byrem et al. (27) evaluated the direct action of a type 2 β-agonist on muscle protein accretion in vivo by closed arterial infusion of cimaterol into a single hindlimb for 21 days in growing steers. Net protein accretion in the treated limb was estimated to have increased by 65% compared with that in the contralateral, saline-infused limb. Hilton et al. (28) reported that the estimated carcass fat from the 9th, 10th, and 11th rib dissections was significantly less in steers, whereas estimated carcass moisture was significantly greater by zilpaterol supplementation. The apparent improvement in the efficiency of energy retention per unit DMI in finishing lambs may be due to the direct action of the ZH on net protein retention and hence lean tissue growth (29).
Visceral organs mass
Based on Table 5 , increases in EBW with no differences in the relative value of EBW as a percentage of final BW were observed when sheep were fed zilpaterol. Previous data suggest that the repartitioning effects due to type 2 β-agonists are not restricted to carcass tissues because the amount of internal fat was significantly less in lambs fed clenbuterol than in controls (26) . Supplementation with a type 2 β-agonist caused a decrease in visceral organ mass (gastrointestinal tract and/or liver) in rats (30) . Similarly, a reduction in kidney (7.5%) and heart (15.4%) mass was previously reported in lambs fed with type 2 β-agonist cimaterol (26) . ZH supplementation decreased liver weight by 9.5% in lambs (12) . However, in contrast to the present report, there was no effect of ZH supplementation on organ mass (expressed as percentage of BW) in steers (3). In summary, daily ZH supplementation of 0.20 mg/ kg BW for the last 30 days of the finishing phase improved daily gain and feed efficiency in castrated goats. In addition, this compound increased HCW and dressing percentage and decreased visceral fat. The increases in dressing percentage and LM chemical characteristics can be direct results of greater muscle accretion, and reduction in organ weights, and decreased visceral fat.
